StocksMediumUpdated×3•Originally published 12 November 2026•Updated 12 November 2026•
4 min read

DarioHealth Revenue Rises 6% to $5.3 Million in Third Quarter of 2026

By

Key Facts

1Third-quarter revenue was $5.3 million, up 6% year over year and 3% from the previous quarter.
2Direct-to-consumer sales rose about 48% year over year, while business revenue declined because legacy contracts were not renewed.
3Operating loss was $8.0 million, compared with $9.5 million a year earlier and $6.5 million in the previous quarter.
4The company has more than 180 signed accounts and $13.1 million in contracted recurring revenue and advanced opportunities.

DarioHealth said its revenue in the third quarter of 2026 rose 6% year over year and 3% from the previous quarter to $5.3 million, according to a company statement published on November 12. The company said direct-to-consumer sales surged about 48% year over year, making them the main driver of revenue growth during the period. By contrast, business-to-business and business-to-business-to-consumer revenue declined from 2025, as several legacy Twill contracts were not renewed. Growth from channel partners offset part of the decline, the statement said. Zacks reported that adjusted loss was $0.44 per share, compared with an expected loss of $0.51, and that revenue exceeded its estimate by 2.14%.

Gross profit was $3.1 million in the third quarter, compared with $3.0 million in the same period of 2025 and $3.2 million in the second quarter of 2026. The GAAP gross margin was about 59%, compared with 60% a year earlier and 62% in the previous quarter. The company attributed the year-over-year margin decline to a higher share of direct-to-consumer sales in the revenue mix. It linked the decline from the second quarter to a lower benefit from tariff refunds. In its B2B2C business, the company said adjusted gross margin remained about 80% for the eleventh consecutive quarter, keeping the segment's margin stable despite changes in the overall mix.

Operating expenses fell to $11.2 million from $12.5 million in the third quarter of 2025, but rose from $9.7 million in the second quarter of 2026. Operating loss was $8.0 million, compared with $9.5 million a year earlier and $6.5 million in the previous quarter. Net loss also narrowed year over year to $8.8 million from $10.5 million, but increased from $7.9 million recorded in the second quarter. The comparison shows losses declining year over year while widening sequentially, alongside expenses rising from their level in the previous quarter. For the first nine months of 2026, revenue was $16.1 million, compared with $17.1 million in the same period of 2025. The company attributed the decline mainly to non-recurring revenue from a pharmaceutical partner recorded in the previous year.

Cash, cash equivalents and short-term deposits totaled $31.2 million on September 30, 2026, the company said. On the commercial front, DarioHealth announced a contract with one of New Jersey's largest health plans, which covers 1.5 million people. It said this was the third statewide health plan it had signed through its Amwell partnership in the 12 months before the announcement. The company is also working with a national health plan customer to make GLP-1 treatment available through the customer's member marketplace. Chief Executive Erez Raphael said the company sees consumer care and payer-funded chronic care converging, adding: "We believe the two are moving toward convergence, and Dario is at the intersection."

DarioHealth said it has more than 180 signed employer and health plan accounts, with $13.1 million in contracted annual recurring revenue and advanced opportunities, more than 80% of which are tied to multi-condition opportunities. It said about 40% of this contracted recurring revenue and advanced opportunities comes from administrative-services-only agreements with health plans, which provide access to the self-insured employer base. Revenue from these agreements accrues over several years as each employer is activated. Raphael said health plans are moving from buying programs tied to a single treatment to buying an integrated, multi-condition platform. The company expected revenue to accelerate at the end of 2026 and continue accelerating through 2027, driven mainly by converting contracted recurring revenue into recognized revenue, as well as new enterprise customers and multi-condition expansions that include Dario Women and Dario Sleep.

The third-quarter earnings conference call was announced for November 12, 2026, at 8:30 a.m. Eastern time, with online access available. In the previous trading session, the company's DRIO shares closed at $2.13 on November 11, according to EL7 data. This comes as the company ties its next phase of growth to converting contracts and commercial opportunities into realized revenue. That path includes expanding multi-condition services and working with health plans, alongside growth in direct-to-consumer sales. The contrast between improved year-over-year results and a higher operating loss than in the previous quarter remains part of the performance picture presented by the company.

Sources

Open on chart